X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Under the licensing agreement, AbbVie to develop OSE-230, a monoclonal antibody designed to resolve chronic and severe inflammation, currently in the pre-clinical development stage.
Lead Product(s): OSE-230
Therapeutic Area: Immunology Product Name: OSE-230
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: AbbVie Inc
Deal Size: $713.0 million Upfront Cash: $48.0 million
Deal Type: Licensing Agreement April 16, 2024
Details:
The funding aims to support the company to focus on the clinical development of Tedop (OSE2101) neoepitope-based cancer vaccine. It is being evaluated in the clinical trial for the treatment of HLA-A2 positive non-small cell lung cancer.
Lead Product(s): OSE2101
Therapeutic Area: Oncology Product Name: Tedopi
Highest Development Status: Phase IIIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Bpifrance
Deal Size: $9.0 million Upfront Cash: Undisclosed
Deal Type: Funding April 10, 2024
Details:
The partnership aims to focus on the development of OSE-230, which is an agonist antibody against ChemR23. It is being evaluated in the preclinical trial studies for the treatment of chronic and severe inflammation.
Lead Product(s): OSE-230
Therapeutic Area: Immunology Product Name: OSE-230
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: AbbVie Inc
Deal Size: $713.0 million Upfront Cash: $48.0 million
Deal Type: Partnership February 28, 2024
Details:
BI 770371 is a novel antagonist anti-SIRPα monoclonal antibody (mAb) targeting both V1 and V2 SIRPα alleles makes SIRPα antagonists an option for more cancer patients.
Lead Product(s): BI 770371,Ezabenlimab
Therapeutic Area: Oncology Product Name: BI 770371
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 23, 2023
Details:
The funding will be used for the development of a companion diagnostic for the pivotal Phase 3 clinical trial of Tedopi (OSE2101), a neoepitope-based, off-the-shelf, cancer vaccine, in non-small cell lung cancer (NSCLC) second line treatment.
Lead Product(s): OSE2101
Therapeutic Area: Oncology Product Name: Tedopi
Highest Development Status: Phase IIIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Bpifrance
Deal Size: $1.6 million Upfront Cash: Undisclosed
Deal Type: Funding June 20, 2023
Details:
Tedopi (OSE2101) is a neo-epitope-based vaccine, is a proprietary combination of nine optimized neo-epitopes, selected and optimized from 5 tumoral antigens to activate specifically T cells, plus one epitope giving universal helper T cell response targeting T cell activation.
Lead Product(s): OSE2101
Therapeutic Area: Oncology Product Name: Tedopi
Highest Development Status: Phase IIIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 15, 2023
Details:
Tedopi (OSE2101, innovative neoepitope combination): the Company’s most advanced product; positive results for Phase 3 trial (Atalante 1) in Non-Small Cell Lung Cancer patients in secondary resistance after checkpoint inhibitor failure.
Lead Product(s): OSE2101
Therapeutic Area: Oncology Product Name: Tedopi
Highest Development Status: Phase IIIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 23, 2022
Details:
VEL-101/FR104 is a novel investigational maintenance immunosuppressive agent being developed for prevention of acute rejection in kidney transplant recipients.
Lead Product(s): FR104
Therapeutic Area: Immunology Product Name: VEL-101
Highest Development Status: Phase IProduct Type: Large molecule
Recipient: Veloxis Pharmaceuticals
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 18, 2022
Details:
BI 765063 (OSE-172, anti-SIRPα mAb on CD47/SIRPα pathway), developed in partnership with Boehringer in advanced solid tumors; positive Phase 1 dose escalation results of BI 765063 in monotherapy and in combination with ezabenlimab (PD-1 antagonist); ongoing expansion Phase 1.
Lead Product(s): OSE-172,Ezabenlimab,Cetuximab
Therapeutic Area: Oncology Product Name: BI 765063
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Boehringer Ingelheim GmbH
Deal Size: $1,352.0 million Upfront Cash: $18.4 million
Deal Type: Collaboration May 03, 2022
Details:
OSE-279 is a humanized anti-PD1 monoclonal antibody blocking PD-L1 and PD-L2, the ligands of PD1 overexpressed by tumor cells. PD-L1 and PD-L2 are used by tumor cells to escape the immune system.
Lead Product(s): OSE-279
Therapeutic Area: Oncology Product Name: OSE-279
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 21, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
